Latest news

• Sun Pharma passes milestone with novel psoriasis drug approval

  Meanwhile, AbbVie has an IL-23 blocker called risankizumab in late-stage testing that it thinks could be a best-in-class treatment and a $1bn-plus contender in psoriasis.

• AbbVie reports more solid data for would-be psoriasis blockbuster

  AbbVie reports more solid data for would-be psoriasis blockbuster. Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... suggested trials to date show risankizumab might be a little better than its rival with the

• AbbVie risankizumab trials set up psoriasis filing - and a market battle

  Competes against blockbusters Stelara and Humira. AbbVie has posted a trio of positive phase III trials for its interleukin-23 inhibitor risankizumab, setting up regulatory applications but also a tough entry ... Depending on the dose, 84% to 88% of

• Archive listing

  Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. .